A new trading day began on Tuesday, with Ocular Therapeutix Inc (NASDAQ: OCUL) stock price down -1.60% from the previous day of trading, before settling in for the closing price of $11.27. OCUL’s price has ranged from $5.78 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 8.51% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -17.19%. With a float of $133.28 million, this company’s outstanding shares have now reached $159.26 million.
In an organization with 274 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.66%, operating margin of -342.52%, and the pretax margin is -323.44%.
Ocular Therapeutix Inc (OCUL) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ocular Therapeutix Inc is 16.33%, while institutional ownership is 74.22%. The most recent insider transaction that took place on Jun 02 ’25, was worth 111,581. In this transaction Chief Medical Officer of this company sold 13,861 shares at a rate of $8.05, taking the stock ownership to the 206,805 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Officer proposed sale 13,861 for $8.05, making the entire transaction worth $111,524.
Ocular Therapeutix Inc (OCUL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -17.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.11% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Here are Ocular Therapeutix Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Let’s dig in a bit further. During the last 5-days, its volume was 2.77 million. That was better than the volume of 1.75 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 90.09%.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 93.32%, which indicates a significant increase from 86.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.52 in the past 14 days, which was higher than the 0.52 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.53, while its 200-day Moving Average is $8.54. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $11.40. Second resistance stands at $11.71. The third major resistance level sits at $11.95. If the price goes on to break the first support level at $10.85, it is likely to go to the next support level at $10.61. The third support level lies at $10.30 if the price breaches the second support level.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
With a market capitalization of 1.77 billion, the company has a total of 159,300K Shares Outstanding. Currently, annual sales are 63,720 K while annual income is -193,510 K. The company’s previous quarter sales were 10,700 K while its latest quarter income was -64,050 K.
